Update in Chlamydia trachomatis vaccinology

Luis M. de la Maza1
Guangming Zhong2
Robert C. Brunham3

1Department of Pathology and Laboratory Medicine
University of California, Irvine
USA

2Department of Microbiology and Immunology
University of Texas Health Science Center at San Antonio
USA

3Vaccine Research Laboratory
University of British Columbia Center for Disease Control
Canada

*Corresponding author
Luis M. de la Maza
Department of Pathology and Laboratory Medicine,
Medical Sciences I, Room D440
University of California, Irvine
Irvine, CA 92697-4800, USA
Phone: (949) 824-7450
Fax: (949) 824-2160
Email: Imdelama@uci.edu
Abstract

Attempts to produce a vaccine to protect against \textit{Chlamydia trachomatis} (\textit{C. trachomatis}) induced trachoma were initiated more than 100 years ago and continued for several decades. Using whole organisms protective responses were obtained. However, upon exposure to \textit{C. trachomatis}, disease exacerbation developed in some immunized individuals precluding the implementation of the vaccine. Evidence of the role of \textit{C. trachomatis} as a sexually transmitted pathogen started to emerge in the 1960's and soon became evident that it can cause acute infections and long term-sequelae in women, men and newborns. The main focus of this Minireview is to summarize recent findings and discuss formulations, including antigens, adjuvants, routes and delivery systems for immunization, primarily explored in the female mouse model, with the goal of implementing a vaccine against \textit{C. trachomatis} genital infections.

Keywords

\textit{Chlamydia trachomatis} vaccines, \textit{Chlamydia muridarum}, antigens, adjuvants, routes of immunization, delivery systems.

Historical background

\textit{Chlamydiae} infections are widespread throughout the animal kingdom (1-3). Until recently, trachoma was thought to be the most common clinical manifestation in humans (1, 2). Trachoma likely first appeared in China and Mesopotamia (~ 2,700 B.C.) and then spread to the Middle East and the Mediterranean region (1, 2, 4).

In 1907 Halberstaedter and von Prowazek (5), using the Giemsa stain, first described the presence of intracytoplasmic inclusions in conjunctival scrapings from monkeys, However, it was not until 1957 that Tang et al., (6, 7), utilizing chick embryos, isolated \textit{Chlamydia} from humans with trachoma although the lymphogranuloma strains have been grown in the yolk sac since 1942 (2, 8).
In 1913, a group in Tunis, led by Nicolle, initiated vaccine studies in humans and non-human primates (9). Resistance to rechallenge was observed in some individuals but in others a worse disease occurred. Major efforts to produce a vaccine using live or inactivated Chlamydia occurred after the isolation of the organisms by Tang et al. (6, 7). Four research groups (1, 2, 4) performed vaccine trials and reached similar conclusions: some vaccine formulations were protective for a period of 1-3 years, the protection was serovar/serogroup specific and certain immunized individuals, upon reexposure, developed more severe disease than the placebo-treated groups (8, 10-16). In a few instances a higher attack rate was observed in vaccinated children than in controls (17, 18). Although Bietti’s laboratory manufactured a vaccine it was never implemented in humans (16).

Improvements in sanitary and hygienic conditions have resulted in the disappearance of trachoma from most parts of the world. In 1993, with the goal to eradicate trachoma by 2020, WHO implemented the SAFE strategy (2, 19). This plan includes (S) surgery for trichiasis, (A) antibiotic treatment of active trachoma, (F) facial cleanliness and (E) environmental improvements focusing on providing water supply, toilets, and fly reduction to the affected areas.

The presence of C. trachomatis in the genital tract was first indirectly described when a nongonococcal, or amicrobiana, ophthalmia was observed in newborns (20). In 1910 Heyman (21) noted the presence of inclusions in samples from the cervix of the mother and the urethra of the father of an infant with inclusion blennorrhea. It is even possible that the identification of Chlamydia in the genital tract was described earlier as the cause of an amicrobial urethritis (22).

Using the yolk sac technique, Jones et al. (23) first recovered C. trachomatis from the cervix of a mother with pelvic inflammatory disease (PID). In the 1970's the introduction of tissue culture techniques greatly improved the ability to isolate Chlamydia from the genital tract of males and females and newborn’s eyes (1, 2).
C. trachomatis is now recognized as the most common sexually transmitted bacterial infection with approximately 100-150 million new cases occurring a year worldwide affecting 68 million females (24-26). Most of the infections (70-80%) in women are asymptomatic however, it is estimated that 5 out of 1,000 will develop tubal factor infertility (27-29). The long-term sequelae of a C. trachomatis infection in females with PID include chronic abdominal pain, ectopic pregnancy and infertility (27, 29-37). Screening and treating females may increase the rates of reinfection but reduces the incidence of PID (31, 38-40). In males, epididymitis but not infertility, is the most severe complication (1, 41). Reactive arthritis (Reiter’s syndrome: urethritis, conjunctivitis and arthritis) has also been associated with Chlamydia (1, 41). In females, most cases of upper genital pathology are due to a single episode of PID. For example, in the pioneering work by Westrom et al., (30) 1,844 women with laparoscopically verified PID and 657 women with normal laparoscopic results were studied over a period of several years. Of the 1,241 that had episodes of PID, 141 were not able to conceive. Tubal factor infertility was associated with the severity and number of PID episodes. The majority of women who were not able to conceive, 56% (79/141), had a single PID episode and in most of them, 62% (49/79), the episode was severe. The number of PID episodes also affected the chances of developing tubal infertility. Of the individuals that had a single episode, 8.0% (79/991) became infertile, while 19.5% (16/185) of those that had two episodes and 40.0% (26/65), of patients who had three or more episodes, were infertile. The ectopic pregnancy rate for first pregnancy after index laparoscopy was 1.4% in controls and 9.1% among patients. Prevention of these long-term sequelae is the principal goal of a vaccine (26, 42-51).

Immunity to C. trachomatis genital infections

Natural immunity in humans

It is well known that genital chlamydial infections are more frequent in young sexually active individuals, between the ages of 15 - 20, than in older persons (24, 52, 53). This finding
has been interpreted as evidence of naturally induced protective immunity. Some clinical and experimental evidence support this suggestion. For example, in sex workers, resistance to infection correlates with duration of prostitution, independently of age, indicating development of acquired immunity (54). Geisler et al. (55) also showed that natural immunity occurs in females with a *C. trachomatis* genital tract infection. Because antibiotic treatment interfered with the development of natural immunity, individuals not treated with antibiotics, had fewer reinfections than those treated. However, it is important to note that, at least in mice, resistance to a primary genital infection increases with age suggesting that some physiological processes may account for a lower prevalence of chlamydial infections in older individuals (56, 57).

The use of *C. muridarum* versus *C. trachomatis* in vaccinology studies

The *C. muridarum* isolate, previously called *C. trachomatis* mouse pneumonitis (MoPn) has been extensively utilized to perform studies in mice (44, 45, 58-60). At the genomic level *C. trachomatis* and *C. muridarum* are highly orthologous and thus, it is thought that findings in mice will correlate well with observations in humans (61). There are however significant differences in the pathogenicity of *C. trachomatis* versus *C. muridarum* in the mouse model.

Following a vaginal challenge *C. trachomatis* serovars (A-K) and *C. muridarum* produce in mice quite different acute and chronic diseases. In animals not pretreated with depot-medroxyprogesterone acetate (DMPA), depending on the strain, stage of the estrus cycle and age of the mice, different doses of *C. muridarum* (ID$_{50}$ ~10^4 - > 10^7 IFU), produce severe infection and infertility, while *C. trachomatis* does not (56, 57, 60, 62). When pretreated with DMPA, all strains of mice so far tested, with the exception of A/J and DBA/2J, develop severe infection and long-term sequelae following a vaginal challenge with a low dose of *C. muridarum* (ID$_{50}$ ~ 200 IFUs) (45, 63-67). In contrast, a vaginal infection with *C. trachomatis* in mice pretreated with DMPA, only induces mild, short infections and no long-term upper genital pathology, i.e. hydrosalpinx and/or infertility (32, 63, 68-72). Not even in the highly susceptible
C3H/HeJ mice, that have a mutated non functional TLR-4 receptor, a vaginal infection with \emph{C. trachomatis} serovar D (strain UW-3Cx) elicits long term tubal pathology (73).

Two publications have reported infertility, without hydrosalpinx formation, following single or multiple vaginal infections with very high doses ($\sim 10^6$ or $10^7$ IFUs) of \emph{C. trachomatis} serovars D or E in mice pretreated with DMPA (74, 75). The lack of hydrosalpinx in these mice suggests that no gross long-term damage was produced in the fallopian tube and therefore, other mechanisms(s), that may or may not be relevant to humans, had to account for the infertility.

Hadad et al. (76) recently reported infertility in mice following a vaginal challenge with $3 \times 10^4$ IFUs of a clinical serovar D isolate. The histopathological findings were not discussed. The apparent high virulence of this serovar D isolate is unusual and needs confirmation.

Sturdevant and Caldwell challenged the validity of using \emph{C. trachomatis} in vaccinology (77). These authors reported that C57BL/6 Rag1-/- mice, which lack mature T and B cell immunity, treated with DMPA, cleared a vaginal infection with \emph{C. trachomatis} serovar D (D-LC) suggesting that innate immunity is sufficient to control the infection. Interestingly, C3H/HeN male mice, with severe combined immunodeficiency (SCID), cannot control a urethral challenge with \emph{C. trachomatis} serovar D (UW-3/Cx) while the WT mice can (78). Finally, following transcervical, intrauterine or intrabursal infections, in mice pretreated with DMPH, not all \emph{C. trachomatis} serovars/isolates induce infertility in most strains of animals while \emph{C. muridarum} does (79-87).

In conclusion, in our opinion, further testing of \emph{C. trachomatis} isolates is needed to validate their use in vaccine studies. The production of a humanized mouse model could help to address some of the limitations (88). In the meantime \emph{C. muridarum} allows us to reproduce in mice the mild and severe acute and chronic infections that \emph{C. trachomatis} produces in humans. The main shortcoming of \emph{C. muridarum} is the lack of isolates that will allow testing for cross-serovar protection.
Immunity to C. muridarum in the mouse model

Characterizing immune responses in humans is extremely difficult since each individual has a different immunogenetic background, infection can occur at birth, or shortly thereafter, be asymptomatic, there is cross-reactivity among different species of Chlamydia and keeping track of sexual behavior in humans is difficult (1, 32, 59). Therefore, most of what we know about protective immunity against chlamydial infections is based on work performed in the mouse model. Using WT and KO mice for genes involved in cellular and humoral immune responses, cytokines and chemokines, passive transfer of T-cells and antibodies, immune components that play a role in protection against a primary and a secondary genital C. muridarum challenges have been determined (44, 45). From these studies it was found that MHC-II restricted CD4+T-cells are required for protective immunity while MHC-I restricted CD8+T-cells are not essential for resolution of a primary infection, or protection against a genital reinfection (64, 89-91).

Human data supports these findings. For example, HIV-1 infected patients, who have low CD4+T-cell counts, are at a higher risk of getting genitally infected with C. trachomatis and developing long-term sequelae than normal individuals (92). Although CD8+T-cells play a critical role in protection against most intracellular pathogens, they are not required to control chlamydial infections. Interestingly, Igietseme et al. (93) showed that clones of CD8+T-cells, likely by producing IFN-γ, enhance clearance of a C. muridarum genital infection and Nogueira et al. (94) demonstrated that cross-mucosa protection (respiratory and genital), is mediated by CD4+ and CD8+ T-cells and not by antibodies.

Following vaccination some of the circulating Th1 lymphocytes may become mucosal tissue-resident memory cells (Trm) rapidly reducing C. muridarum load upon reinfection (85, 95). This hypothesis is consistent with the detection of CD4+ T cells in the mouse genital tract tissues long after the infection was cleared (96). These lymphocytes once deposited locally may protect against microbial invasion in both antigen-specific and –nonspecific means and even...
undergo autonomous proliferation (97-99). Thus, as first proposed by Morrison and Morrison, an effective *C. trachomatis* vaccine may need to induce Trm in the genital tract mucosa (95, 96).

The role of B cells and/or antibodies against a primary infection is not clear. However, they have been found to be as protective as CD4+T cells against reinfection, making them important in vaccine development (90, 100-102). Following a primary *C. muridarum* infection of the genital tract, mice are resistant to a rechallenge if CD4+T-cells and/or antibodies are present (100, 103, 104). Antibody deficient mice and those that lack Fc receptors, resolve a primary *C. muridarum* genital infection, but not a secondary infection, as well as WT animals (44, 64, 90, 100).

Considering the extraordinary complexity of the antibody response, it is not surprising that in humans and animal models, some antibodies have been found to be protective while others correlated with pathogenesis. For example, high levels of antibodies to the *C. trachomatis* 60-kDa-heat shock protein (Hsp60) have more often been detected in patients with long-term sequelae than in individuals without complications (105-107). However, high IgA levels in the genital tract protect mice against a *C. muridarum* infection and correlate with protection against the long-term sequelae (108, 109). In humans, mucosal antibodies especially IgA, correlate with reduced bacterial shedding (108). Also, even in the absence of T-cells, passive immunization of mice with monoclonal antibodies can control a primary *C. muridarum* infection (110, 111).

Th1 cytokines, particularly IFN-γ and IL-12, are needed for protection against *C. muridarum* (112, 113). In contrast IL-10, a Th2 cytokine, was found to be associated with pathological responses (114). The critical role of IFN-γ against chlamydial infections has been demonstrated using neutralizing antibodies and by showing that mice deficient in IFN-γ, or its receptor, do not resolve a primary *C. muridarum* genital infection (112, 115). These animals develop a systemic dissemination but are partially protected against reinfection (101, 113, 116).
In conclusion, based on the evidence we have in mice infected with C. muridarum, to elicit optimal protection a chlamydial vaccine will have to induce CD4+T cells with Th1-biased cytokines, in particular IFN-γ, and humoral responses in particular mucosal antibodies.

C. trachomatis vaccine antigens

Whole-cell vaccines

In mice, intranasal immunization with live EB was the first approach shown to elicit very robust protection against a C. muridarum genital infection (117, 118). Following an intrabursal challenge, vaccinated mice showed significant decrease in vaginal shedding and, more importantly, protection against infertility. This protection was found to be long-lived and also protected newborn mice suggesting that a live chlamydial vaccine could be effective in very young individuals before sexual maturity (119, 120). As determined by vaginal shedding, intranasal inoculation with live EB was also found to protect mice against a vaginal challenge with C. trachomatis serovar E (Bour) (121). Protection with C. muridarum UV-inactivated EBs was not as effective as that obtained with viable organisms and reticulate bodies were not protective (121-124). UV-inactivated serovar E (Bour) EB, adjuvanted with AS01B, as determined by shedding, were shown to induce cross protection against vaginal and intrauterine challenges with serovar K (UW-31/Cx) (125). Adoptive transfer of dendritic cells pulsed ex vivo with inactivated C. muridarum EB achieved very strong protection that was considered to depend on IL-12 production by the pulsed dendritic cells (126, 127). These results support further investigation on testing non-viable Chlamydia whole-organisms as vaccines.

The use of a live attenuated EB vaccine is another potential approach. Mice inoculated vaginally with a plasmid-cured isolate of C. muridarum developed an infection with a similar course to that following inoculation with the WT isolate, but no upper genital pathology was observed (128, 129). Following a subsequent challenge with the WT isolate, animals first infected with plasmid-cured C. muridarum had less upper genital pathology than those first
inoculated with WT. However, there was minimal protection against vaginal shedding and the mice were not tested for their fertility status. Similar findings were reported when plasmid-cured C. muridarum was inoculated into the ovarian bursa (129). Mice vaccinated with a plasmid-cured C. trachomatis serovar L2R had reduced shedding but no upper genital tract protection against a challenge with serovar D (UW-3Cx) (130).

Studies in non-human primates have also shown that vaccination with plasmid-cured C. trachomatis serovar A, at least in animals that shared a common MHC II class allele, can induce protection against ocular infection and disease (131). Additional work however, is required before this approach is tested in humans. For example, Qu et al. (132) showed that cervical inoculation of Rhesus macaques with WT, or plasmid-deficient C. trachomatis serovar D (UW-3Cx), resulted in the same levels of infection, immunity and pathology in the genital tract. This suggests that the plasmid is not required for C. trachomatis to colonize the genital tract of Rhesus macaques. However, the plasmid appears to be important for C. trachomatis infection of the human genital tract since most human isolates are plasmid-competent (133, 134).

It is not clear why live Chlamydia induced better protective immunity than killed organisms (122-124). Replication and dissemination of live Chlamydia will broaden and expand the antigenic load (135). Also, one distinguishing feature is that inactivated organisms load far fewer peptides onto dendritic cell MHC II molecules than do viable organism (123). However, it will be worth comparing the levels and types of Trm in the genital tracts of mice immunized with live or dead EBs since it was recently demonstrated that the requirement for viability to induce protective immunity could be overcome by using adjuvantized nanoparticles, which correlated with the induction of transmucosal Trm (85).

Subunit vaccines

Introduction
Safety concerns about the negative effects observed during the trachoma vaccine trials and costs of production have encouraged the formulation of a *C. trachomatis* subunit vaccine.

Based on the trachoma vaccine trials, the protection against an ocular challenge was found to be serovar/serogroup specific an observation supported in mice experiments (1, 2, 136, 137). DNA sequencing of the major outer membrane protein (MOMP) and computational analysis established that MOMP was likely responsible for the protection observed during the trachoma vaccine trials (137-140). Initial attempts to vaccinate animals with *C. muridarum* recombinant MOMP (rMOMP), peptides corresponding to the variable domains (VD), or with DNA plasmids that expressed this protein were not encouraging (65, 141-145) (143). In addition, the expected serovar/serogroup specificity of the protection elicited with MOMP was, and still is, a significant concern. For these reasons, the search for additional protective antigens was undertaken.

Initially, an empirical approach was used and several proteins, in particularly those localized to the outer membrane of *Chlamydia*, were tested. Since the availability of the *Chlamydia* genome sequence and implementation of protein microarrays, it became possible to identify chlamydial antigens that can induce antibody and/or cell-mediated immune responses in infected individuals (107, 146-158). Identification of immunogenic components using these approaches however, does not imply that they are going to be protective. Therefore, it is necessary to test these antigens in animal models to demonstrate their protective ability.

**Major outer membrane protein (MOMP)**

MOMP is a 40-kda protein that accounts for approximately 60% of the mass of the outer membrane of *Chlamydia* (159, 160). Structurally MOMP has four VD, which define the uniqueness of each serovar, alternating with five constant domains (CD) (138, 139). Like porins from other Gram-negative bacteria MOMP has a trimeric structure (161). However, unlike most bacterial membrane proteins, MOMP is highly disulfide cross-linked with other cysteine rich proteins forming an intermolecular network that may account for the structural rigidity of the
outer membrane of EB since *Chlamydia* has limited amounts of peptidoglycan (162-165). In humans and animals, MOMP is an immunodominant antigen that has multiple T-cell and B-cell epitopes and can induce T-cell immunity and neutralizing antibodies (166-170).

The first evidence that a subunit *Chlamydia* vaccine could protect mice against a genital challenge was reported in 1997 (171). Mice immunized using a detergent extracted chlamydial outer membrane complex (COMC), and incomplete Freund’s adjuvant, were protected as determined by the number of *C. muridarum* IFU recovered and fertility rates (171). This study also showed that MOMP, extracted with several detergents, was not as protective as the COMC. The authors postulated that the enhanced protection elicited by the COMC was due to the conservation of the native conformation of MOMP and not due to the additional antigens present in the COMC. In 2001, mice vaccinated with MOMP in its native trimeric conformation (nMOMP), using Freund’s adjuvant, were significantly protected against shedding and infertility, while those vaccinated with denatured nMOMP were not, supporting the critical role of the structure of MOMP in protection (172). The humoral immune responses were lower but the cell mediated immune responses higher in mice immunized with nMOMP versus denatured nMOMP. Pal et al. vaccinated mice with nMOMP, using CpG plus Montanide ISA 720 as adjuvants, and showed very robust protection against an intrabursal challenge with *C. muridarum*. Animals immunized with nMOMP were as protected against shedding and infertility as those immunized intranasally with live EB (169, 173). The importance of the conformation of MOMP for protection was further demonstrated when rMOMP and nMOMP were directly compared, using CpG plus Montanide ISA 720 as adjuvants, for their ability to elicit protection against a respiratory *C. muridarum* challenge in mice (174). Based on changes in body weight, lungs weight and number of IFU recovered from the lungs, nMOMP was significantly more protective than rMOMP. These results have now been confirmed in the genital challenge model (103, 175, 176). Vaccination with nMOMP can protect mice against intrabursal and intravaginal challenges with significant decreases in the number of mice that have positive vaginal cultures,
the number of IFU recovered, length of shedding and infertility rates. In the vaginal model it was shown that nMOMP induced protection requires both CD4+ T cells and antibodies (103). Importantly, vaccination of non-human primates with the *C. trachomatis* serovar A (A2497) nMOMP, formulated with CpG-2395 and Montanide ISA 720, protected against an ocular challenge with the same serovar, as shown by a significant decrease in shedding (177). However, no protection was observed against inflammatory responses.

Immunization with *C. muridarum* rMOMP using various adjuvants has shown promising results in animal models (174, 176, 178, 179). For example, Hansen et al. (178) immunized mice with rMOMP and the cationic liposome 1 (CAFO1) and, as determined by a reduced chlamydial load, obtained protection against a vaginal challenge but hydrosalpinx formation was not prevented. Hickey et al. (179) administered rMOMP orally with a novel lipid-based adjuvant, resulting in significant protection against vaginal shedding although *C. muridarum* was still present on the last culture day (18 days post infection). No difference in the inflammatory response in the genital tract was noticed at 28 days post-infection. The authors proposed that the lack of protection in the rMOMP-immunized animals against tissue pathology was due to the influence of the treatment with DMPA before the vaginal challenge (179). Carmichael et al. (176), using *C. muridarum* rMOMP, CpG plus Montanide ISA 720 as adjuvants and a combination of mucosal and systemic routes for immunization, showed for the first time protection against vaginal shedding and infertility using a recombinant antigen. Badamchi-Zadeh et al. (180) constructed a consensus MOMP from variant sequences of *C. trachomatis* serovar E. The consensus MOMP transgene was delivered using plasmid DNA, human adenovirus 5 (HuAd5) and/or modified vaccinia Ankara (MVA). The DNA-HuAD5-MVA-Protein regimen was used to immunize BALB/c and B6C351 mice. Based on vaginal shedding, minimal protection was observed against an intravaginal challenge with serovar D (UW-3/Cx).

Olsen et al. (181) recently tested a multivalent vaccine containing the VD4s and surrounding CDs of MOMP, from *C. trachomatis* serovars D, E and F. This construct,
adjuvanted with CAF01, elicited in mice immune responses some of which were serovar specific, others to the conserved VD4 epitope (LNPTIAG) and neutralized in vitro serovars D, E, and F. Vaginally challenged mice were protected as determined by the number of C. trachomatis serovar D (UW-3/Cx) IFU recovered from the vagina and prevention of the inflammatory response in the upper genital tract. T-cell depletion and passive transfer of serum experiments provided evidence of the critical role of CD4+ T cells and antibodies in protection. Using the same MOMP construct, plus CT043 and CT414 antigens, investigators from the same laboratory elicited neutralizing antibodies and weak protection against vaginal shedding in minipigs challenged with serovar D (182). Hadad et al. (76) have reported that a construct consisting of the VD2/VD4 regions of C. trachomatis serovar E, adjuvanted with cholera toxin, protected mice against a vaginal challenge with a clinical serovar D isolate. The authors observed a decrease in vaginal shedding during the first two weeks after the challenge and protection against infertility.

Polymorphic membrane proteins (Pmps)

Genome sequencing uncovered the presence of a family of Pmps unique to Chlamydiales (138). In C. trachomatis and C. muridarum there are nine pmp genes and, based on the presence of a C-terminal phenylalanine, a peptide leader sequence and proteomic studies, these proteins were predicted to be located in the outer membrane (183-185). Pmps have MW ranging from ~100-150 kDa, contain β-barrel domains in the C-terminus and in their N-terminal regions motifs that have been associated with adhesion to the host cells (186). Based on their structure, they are considered to be type V secretion autotransporters, which mediate the translocation of the N-terminus to the bacterial surface. In addition, some of these proteins contain poly G tracts that control the phase variable expression of the genes providing a means by which organisms can evade host immune responses (187). Pmps have been found to be immunogenic in humans, non-human primates and mice infected with C. trachomatis or C.
**muridarum** (151, 153, 156, 188, 189). Antibodies to PmpA have been associated with decreases in fertility and live births (190).

In 2006 Crane et al. (191) reported that antibodies to PmpD could neutralize in vitro all the *C. trachomatis* serovars. Paes et al. (192) vaccinated mice with PmpD from *C. trachomatis* serovar E (Bour), using a synthetic agonist to TLR4 as adjuvant, and based on vaginal shedding, observed protection against a challenge with serovar D (UW-3/Cx). Karunakaran et al. 2008 (193) using an immunoproteomic approach discovered novel T cell epitopes in several *C. muridarum* Pmps (E, F, G and H). Vaccination of C57BL/6, BALB/c and C3H/HeN mice with N-terminal fragments from each of these four proteins was shown to confer protection against a vaginal challenge as determined by accelerated clearance of *C. muridarum*. In particular, PmpG elicited the best protection. A polyvalent recombinant vaccine, consisting of the four Pmps from serovar D, and MOMP s from serovars D, F and J, formulated with the Th1 polarizing adjuvant DDA/MPL, as determined by vaginal shedding, protected C57BL/6 mice against a transcervical challenge with *C. trachomatis* serovar D (86). Interestingly, Inic-Kanada et al. (194) found that PmpC from *C. trachomatis* serovar E elicited limited protection in guinea pigs against an ocular challenge with *Chlamydia caviae*.

**Chlamydial protease-like activity factor (CPAF)**

CPAF is a secreted protease highly conserved among all the *Chlamydia* species (99% amino acid identity among the *C. trachomatis* serovars). CPAF is produced as a zymogen and an internal segment, inhibits its proteolytic activity (195). Following dimerization and trans-autocatalytic cleavage active CPAF behaves as a serine protease consisting of a homodimer of catalytic domains, each with two distinct subunits (196). Once in the host cell cytosol, and/or released extracellularly, CPAF may act as a virulence factor by degrading eukaryotic proteins that potentially affect chlamydial colonization (197-201).
CPAF has been found to be a dominant antigen in Chlamydia-seropositive humans and mice (107, 151). Vaccination of mice with C. muridarum CPAF, using IL-12, or CpG as adjuvants, shortens the duration of the infection, decreases oviduct pathology and elicits cross-serovar protection (202, 203). No protection against infertility was obtained following a primary C. muridarum vaginal challenge but it was observed against a secondary challenge (204). The protection against vaginal shedding elicited by CPAF starts 1-2 weeks post-challenge. The delay may be because activated secreted CPAF is only detected after 24 hrs. postinfection. A T-cell epitope from C. muridarum CPAF has been found to be protective in HLA-DR4 transgenic mice suggesting that this antigen may be protective in humans (205). The protection elicited by CPAF is conformation independent, since both the active and the inactive forms of the protein elicit the same levels of protection, and is mainly dependent on CD4+ T cells, producing IFN-γ, with contribution from CD8+ T-cells and antibodies (124, 206, 207).

Plasmid glycoprotein 3 (Pgp3)

Most C. trachomatis isolates have a plasmid that codes for eight proteins including Pgp3 (MW of 28 kDa) (134, 208, 209). Crystallization of this protein from C. trachomatis serovar D, showed it to be an ~84 kDa homotrimer (210). Pgp3 was found in the chlamydial envelope and also in the cytoplasm of the host cell (211, 212). This protein appears to be the major virulence factor encoded in the chlamydial plasmid. Pgp3-deficient C. trachomatis and C. muridarum were highly attenuated and this protein may promote chlamydial colonization by neutralizing host immune effectors (129, 213). However, the precise mechanism by which this protein promotes chlamydial pathogenicity remains unclear. Sera from humans and mice identified the homotrimer but not the monomer as an immunodominant antigen (151, 214). Donati et al. (215) vaccinated C3H/HeN mice with a DNA plasmid expressing C. trachomatis serovar D Pgp3 and a control group with the same plasmid containing an irrelevant insert. As determined by the number of positive salpinx cultures, mice vaccinated with the Pgp3 plasmid, were partially...
protected against a genital challenge with *C. trachomatis* serovar D. Vaccination of mice with *C. muridarum* pgp3, using CpG as adjuvant, elicited protection against a genital challenge (216). Although the role of the plasmid in chlamydial pathogenesis is still not fully elucidated the possibility that some of the plasmid coded proteins may be pathogenic casts doubts about their use as a vaccine. In addition, although relatively rare, plasmidless or with variant plasmids, *C. trachomatis* have been isolated from humans that may not be protected by vaccines using only plasmid antigens such as Pgp3 (134, 208, 217).

**Multivalent vaccines**

Antigens formulated in a multivalent vaccine may have synergistic, additive, neutral or antagonistic effects (155, 218, 219). Several *C. muridarum* antigen combinations have been tested in the mouse model. For example, Finco et al. (155) identified chlamydial antigens that elicited humoral and cell mediated immune responses and combinations of these proteins were tested for their ability to protect mice against an intranasal *C. muridarum* challenge. Mice immunized with TC0106, TC0210, TC0313, or TC0741, adjuvanted with LTK63+CpG had a 0.5-0.9 log$_{10}$ reduction in the number of IFU recovered from the lungs. Two, four-antigen combinations (TC0106, TC0210, TC0313 and TC0741) and (TC0106, TC0431, TC0551 and TC0890) were also tested. The first antigen combination resulted in a 4.1 log$_{10}$ and the second one in a 2.2 log$_{10}$ reduction in the yield of *C. muridarum* from the lungs, indicative of additive effects. Yu et al. (219) also found additive effects in the genital model. Three *C. muridarum* proteins PmpE/F, PmpG, and MOMP or a combination of them, were formulated with three different adjuvants CpG, Abisco, or CAF01, and used to immunize mice. The combination of the three proteins, adjuvanted with CAF01, as determined by vaginal shedding, exhibited the greatest degree of protection against a genital challenge. C57BL/6, BALB/c and C3H/HeN immunized with a multisubunit recombinant vaccine, that included PmpE, PmpF, PmpG, PmpH, and MOMP, and DDA/MPL as the adjuvant, also conferred better protection against a genital
challenge than immunization with single antigens (220). Coler et al. (125) also showed that MOMP combined with CT875 and adjuvanted with AS01B, elicited better protection against a vaginal challenge with *C. trachomatis* serovar K (UW-31/Cx) than the individual antigens.

Neutral effects by combining *C. muridarum* antigens have also been reported. Yu et al. (221) vaccinated mice with PmpE, PmpF, PmpG, Aasf, RpIF, TC0420 or TC0825, adjuvanted with DDA-MPL, and challenged the animals in the genital tract. PmpG elicited the most robust immune response and the best protection as shown by a decrease in the number of IFU recovered. However, three combinations of antigens (PmpE+PmpF+PmpG+PmpH+Tarp; Aasf+RpIF+Rec0; and TC0420+TC0825+TC0285) only protected as well as the best individual protein in the formulation. Similar neutral findings were reported when testing combinations of antigens in the respiratory model (222). Mice were immunized with components of the *C. muridarum* putative ATP synthase complex TC0580, TC0581, TC0582, TC0584 or with MOMP. In addition, TC0582 was formulated in combination with TC0580, TC0581 or MOMP. Animals immunized with combinations of two of these three antigens were only protected as well as mice vaccinated with MOMP, the most protective protein in the formulation. Also, Li et al. (203) reported that the addition of CPAF to MOMP, or IncA, from *C. trachomatis* serovar D (UW3-Cx), did not enhance the CPAF induced effect on *C. muridarum* clearance or oviduct pathology. Based on these results, when formulating a multivalent subunit chlamydial vaccine, it will be necessary to evaluate the interactions between the antigens before implementation.

**Other potential vaccine antigen candidates**

In addition to the above-discussed antigens, other chlamydial proteins have been tested for their ability to induce immune responses and/or protection against infection and/or disease. Several excellent reviews have discussed these findings (45-47, 223-228). Some of the antigens that have been found to elicit protection in the mouse model include the outer membrane protein B (omcB), putative type III secretion effector protein Tarp, macrophage
infectivity potentiator (MIP), CopB, CopD, Cap1 and CT584, the inclusion membrane protein (IncA), porin protein B (porB), the ribonucleoside reductase (NrdB) and glycogen phosphorylase (229-238). The ability of these antigens to induce robust protective immune responses is limited and requires additional testing.

Adjuvants

Most of the current vaccines against microbial pathogens are formulated using live attenuated or whole inactivated organisms (239, 240). Since the discovery of Toll-like receptors (TLRs), it has become clear that microbes contain not only antigenic components, but also other products that, by activating these eukaryotic cell receptors have an adjuvant effect and help stimulate robust and well-defined innate and adaptive host immune responses. According to C.A. Janeway, this mechanism explained the efficacy of whole cell vaccines: “the immunologist’s dirty little secret” (241-245). Thus, when the vaccinated host is exposed to a pathogen, rapid and focused immune responses occur.

The implementation of subunit vaccines, like those for HBV and HPV has required the inclusion of several adjuvants in their formulation to replicate the robust immunological responses elicited by whole organism vaccines (239, 240, 246, 247). Because individual adjuvants are only moderately effective at eliciting broad long lasting protective immune responses and are often targeted to a single type of TLR, there exist a need to use several adjuvants for subunit vaccines. In addition, the distribution of TLRs varies among tissues and thus the need to test adjuvant combinations against pathogens, such as C. trachomatis, that have multiple portals of entry.

The bacterial components with TLR immune adjuvant activity are called pathogen-associated molecular patterns (PAMPs) (248-254). Examples of PAMPs include membrane components i.e. LPS, flagellin, lipoteichoic acid, porins, and intracellular components such as nucleic acids (241, 243). Following a primary infection, some pathogens elicit solid protective
immune responses. For these we can assume that the native antigens and PAMPs present in
the organisms are inducing innate and adaptive immune responses that protect the host against
reinfection (239, 240, 248-254). However, many bacterial, parasitic, and viral primary infections
do not elicit robust protection against a secondary infection. Therefore, against these
pathogens, including *Chlamydia*, it may be necessary to formulate vaccines that elicit "unnatural
immunity" (255). During a *Chlamydia* infection TLR- and nucleotide-binding oligomerization
domain (NOD)1-mediated activation occur (256-258). Several chlamydial PAMPs, including
LPS, MOMP, macrophage infectivity potentiator (Mip), and heat shock protein-60 (hsp60) are
involved in this process resulting in signaling mainly through TLR2 and TLR4 (257, 259-262).
However, all these chlamydial PAMPs, including LPS, induce weak immune responses and this
may explain the lack of robust protection elicited by a primary infection (262).

Initial chlamydial vaccine trials were performed using Alum and oil in water adjuvants,
now known to be Th2-biased adjuvants. When it was found that, at least in the mouse model,
Th1-biased immune responses were necessary to induce protection new adjuvants were tested.
Several studies have used single and adjuvant combinations in vaccine formulations to protect
mice against a *C. muridarum* challenge.

To determine the relative efficacy of single adjuvants the following nine ligands, to TLR
or NOD receptors, were screened for their ability to protect against a *C. muridarum* respiratory
infection: Pam2CSK4 (TLR2/6); Poly (I:C) (TLR3); Monophosphoryl lipid A (TLR4); *B. subtilis*
flagellin (TLR-5); Imiquimod R837 (TLR7); Imidazoquinoline R848 (TLR7/8); CpG-1826 (TLR9);
M-Tri-DAP (NOD1/2) and Muramyl dipeptide (NOD2) (263). Mice were vaccinated with rMOMP,
adjuvanted with each individual agonist, challenge intranasally, and protection was determined
based on changes in body and lungs weights, and the number of IFU recovered from the lungs.
Based on these parameters, the most efficacious adjuvants were Pam2CSK4 and Poly (I:C).
CpG-1826 elicited intermediate protection while monophosphoryl lipid A (MPL) induced minimal
protection (263). Based on the IgG2a/IgG1 ratio in serum, Pam2CSK4 and MPL elicited Th2-
biased immune responses, while CpG-1826 induced strong Th-1 responses and Poly (I:C) balanced Th1/Th2 responses. The lack of correlation between Th-1/Th-2 responses, as determined by the IgG2a/IgG1 ratio, and protection suggest that, by itself, this may not be an adequate immunological parameter to predict protection. CPAF formulated with CpG-1826, or recombinant murine IL-12, as single adjuvants, elicited similar Th-1 immune responses and limited protection against a genital challenge (124, 203, 264, 265).

Several studies have characterized the use of adjuvant combinations to protect against C. muridarum infections. For example, Yu et al. (219) formulated recombinant PmpG-1, PmpE/F-2 and MOMP individually or in combination with three different adjuvants: CpG-1826, AbISco-100 or CAF01. The combination PmpG-1, PmpE/F-2 and MOMP plus CAF01, as determined by C. muridarum shedding, was the most efficacious to protect C57BL/6 and BALB/c mice against a vaginal challenge. The CpG-1826 formulation failed to protect, supporting the need for the use of adjuvant combinations. This group of investigators confirmed those results by testing four adjuvant combinations: DDA-MPL, CAF01, CAF04 and Montanide ISA 720 VG plus CpG-1826 in addition to Alum. PmpG was used as the test antigen. The most robust immune responses and best protection against vaginal shedding were observed when DDA-MPL or CAF01 were utilized as adjuvants (221). These two adjuvant combinations elicited the highest frequency of multifunctional CD4 T cells coexpressing IFN-γ and TNF-α, supporting the role of these cytokines in protection.

Adjuvant combinations have also been tested using MOMP as the antigen. In the genital model, the combination of CpG-1826 plus Montanide ISA 720 VG, a non-Toll receptor adjuvant, has been found to be quite effective, at eliciting protective immune responses, using both nMOMP or rMOMP as antigens (169, 176, 266). MF59, a detergent stabilized oil-in-water emulsion containing squalene and currently in human use, was found to elicit better protection in mice against a genital C. muridarum challenge than when single adjuvants, LT-K63 or LT-RT2, derived from E. coli enterotoxin, were formulated with nMOMP (267). Cheng et al. (268) ...
compared combinations of CpG-1826 with Pam2CSK4 or with Montanide ISA 720 VG. The Pam2CSK4 plus CpG-1826 combination was found to elicit the most robust protection against a *C. muridarum* respiratory challenge (268). IC31® is an adjuvant that combines the oligodeoxynucleotide d(IC)_{13} (ODN1a) with the peptide KLKLLLKLK (KLK) (269). IC31® generates a depot at the injection site and provides immune stimulation via the TLR9/MyD88 pathway (270-272). This adjuvant combination formulated with nMOMP elicited significant protection against a respiratory challenge with *C. muridarum* (273).

**Routes of immunization and delivery systems**

The utilization of a mucosal route for immunization appears to be relevant for protection against mucosal pathogens such as *C. trachomatis*. Mucosal tissues comprise the largest source of immunity in the body and are the first line of defense against many pathogens (274-280). The genital tract is considered to be a component of the common mucosal immune system (CMIS). It is assumed that stimulation of the CMIS results in immune responses at remote mucosal effector sites, but stimulation of the various mucosal inductive sites results in uneven distribution of immune responses at the effector sites. Overall, the most effective way to induce immune responses at a specific effector site is to locally administer the vaccine, or perhaps, stimulate sites with related lymph drainages (117, 176, 279, 281-283).

In addition to eliciting a solid immune response at the entry site, deciding what route to use for vaccination requires evaluation of other factors including safety, ease of use, cost, societal acceptance, and adjuvant availability. Immunization by the intravaginal route seems the most appropriate choice for eliciting protection against genital pathogens. Intravaginal immunization through use of a gel has been successful against cholera, and both Intravaginal and rectal immunizations have been utilized against HIV (239, 284-287) (240). The main limitation of this route is patient acceptance. Furthermore, low IgA and IgG in the vaginal fluid
after vaginal vaccination alone have been reported (279, 281). Oral immunization is readily acceptable (286). A good example is the live polio vaccine. Yet, for subunit vaccines, the need for a successful delivery system and the large amounts of antigen required for robust immune responses severely limit this approach. The sublingual route may be a more desirable alternative and has been successful in mouse models (176, 283, 288). Colonic immunization may also be a target since it has been shown to induce higher vaginal and serum IgA levels than oral and intramuscular immunizations (176, 289). The ease of use and patient acceptance will have to be improved by utilizing oral delivery systems. The intranasal route induces mucosal IgA and stimulates immunity not only in local tissues but also in the genital tract (117, 290, 291).

Unfortunately, intranasal immunization may negatively affect the central nervous system, and this safety issue is why some vaccines have been pulled from the market (287, 292).

Systemic (intramuscular and subcutaneous) and mucosal (sublingual and colonic) routes, alone and in combination, were tested by Ralli-Jain et al. (283) for their ability to protect mice against a C. muridarum respiratory challenge. The best protection was achieved when mucosa, followed by systemic immunizations, were utilized. Carmichael et al. (176) also tested combinations of mucosal (intravaginal, colonic, and intranasal) and systemic (intramuscular and subcutaneous) routes to immunize mice against a vaginal challenge with C. muridarum. The strongest Chlamydia-specific humoral and cell-mediate immune responses were obtained in the groups immunized by a combination of mucosal and systemic routes. As determined by vaginal shedding and fertility rates, animals vaccinated combining mucosal and systemic routes were also the best protected. Mucosal immunization by itself elicited weak immune responses and minimal protection.

Work by Stary et al. (85) supports enhanced protection using a mucosal route for immunization. These authors vaccinated mice with UV-inactivated C. trachomatis serovar D (UW-3/Cx) EBs by the intranasal or intrauterine routes using nanoparticles coupled to R848. Mucosal immunization elicited Trm that migrated to the uterine mucosa eliciting protection...
against a transcervical challenge, while subcutaneous immunization failed to induce Trm and to protect.

Several delivery systems, including DNA plasmids, poliovirus, adenovirus, hepatitis B virus, influenza virus, *Vibrio cholera* ghosts, and nanoparticles have been used to vaccinate mice with various chlamydial antigens (65, 141, 144, 293-300). Although some of these delivery systems offer interesting opportunities, such as the ability to carry antigens from several pathogens, so far the results obtained do not appear to offer significant advantages over well-established approaches. Furthermore, inclusion in a vaccine of not-medically relevant antigens from the delivery system introduces unknown safety issues and may divert immune responses. The use of edible plants is certainly an interesting approach but needs to be carefully evaluated for its possible negative impact (301). Therefore, more work is needed before any of these delivery systems is implemented.

**Cross-serovar protection**

The low virulence of *C. trachomatis* in mice and the lack of *C. muridarum* serovars present a major challenge for testing cross-serovar protection in the mouse model. However, several investigators have addressed this problem. For example, Tuffrey et al. (302) used a recombinant fragment of *C. trachomatis* serovar L1 MOMP to immunized mice and challenged them by the vaginal or the uterine routes with serovar F (NI1). In some groups of vaccinated mice, there was a reduction in the duration of colonization and the severity of the salpingitis. Li et al. (203) constructed a multivalent vaccine that included three recombinant proteins CPAF, MOMP and IncA, from serovar D. Vaccinated mice were challenged vaginally with *C. muridarum*. Immunized mice had less shedding and upper genital tract pathology than the negative control animals. Eko et al. (303) immunized mice with *V. cholera* ghosts expressing porB and/or PmpD from serovar D and challenged them vaginally with *C. muridarum*. The groups vaccinated with one or both antigens had a significant decrease in vaginal shedding. A
different approach was taken by Olivares-Zabaleta et al. Mice were vaccinated intravaginally with the plasmid-free *C. trachomatis* serovar L2 (25667R) and subsequently challenged vaginally with serovar D (UW-3/Cx). Immunized mice were not protected against infection or inflammatory disease but had a reduced infectious burden. By taking advantage of the respiratory model, Tifrea et al. (304) showed that mice immunized with *C. trachomatis* recombinant MOMP from serovars D (UW-3/Cx), E (Bour) or F (IC-Cal-3) can be protected against disease and bacterial burden from a challenge with *C. muridarum*. In conclusion, although we do not have a good mouse model, these results suggest that using a multivalent vaccine it may be possible to elicit solid cross-serovar protective responses.

Can the immunological and protection findings in mice be directly translated to humans?

In evolutionary terms, differences in innate and adaptive immune responses between humans and mice have developed over the last 100 million years when primates and rodents were separating (305-307). Living in contrasting habitats and exposed to different microorganisms has resulted in significant divergence of their immune systems (308-313). In the last 100 years the establishment of inbred strains of mice has added another layer of immunological differences (314). As a result, we cannot be certain that the findings obtained in the mouse model will be directly applicable to humans. Even more, results in one strain of mice may not directly extrapolate to another strain. Here, we will briefly discuss some differences between the innate and adaptive immune systems of humans and mice that may impact the development and implementation of a *C. trachomatis* vaccine.

One of the main defense mechanisms against pathogens in humans and mice is the presence of pattern recognition receptors (PRR), such as the TLRs (10 present in humans and 13 in mice), that activate the innate immune system by binding molecular patterns of microorganisms such as LPS (312, 313, 315, 316). In humans, binding of ligands to TLR causes significant inflammatory responses that help protect against pathogens by limiting their burden.
In contrast, mice respond very weakly to TLR agonists. For example, in humans a dose of ~15 μg/kg of LPS causes severe diseases, including shock, while in mice the LD₅₀ is ~10 mg/kg (309, 317). Furthermore, significant differences are also found between different strains of inbred mice. For example, agonists of TLR-3 were the most effective adjuvants to elicit IFN-γ producing NK, CD4 and CD8 T-cells in C57BL/6 while in BALB/c, TLR-7/8 was found to be the most effective (318, 319).

IFN-γ is released in humans and mice during inflammation to trigger innate immune responses. In mice, IFN-γ induces the expression of the p47 immunity-related GTPase (IRG) proteins that include 18 genes and IRG knockout mice are highly susceptible to pathogens (320). Humans express only two IRG proteins and none of them are induced by IFN-γ. In mice, IFN-γ induces three different IRG genes against *C. trachomatis* that leads to rerouting of the inclusions to autophagosomes (321). *C. muridarum* in contrast has a large toxin with homology to Yop7 that blocks the interaction of IRG proteins with the inclusion membrane (112). In addition, in human epithelial cells IFN-γ elicits expression of indoleamine 2,3-dioxigenase that, by depleting the host tryptophan pools, inhibits the growth of *C. muridarum*. *C. trachomatis* however, can grow by producing a tryptophan synthase that may use indole generated by microbes in the human genital tract to produce tryptophan (88, 322).

The leukocyte composition of humans and mice is also significantly different. Humans have 50-70% neutrophils and 50-30% lymphocytes while mice have only 10-30% neutrophils and 90-70% lymphocytes (312, 313). In addition to differences in proportions there are also functional differences between human and mice neutrophils. For example, human neutrophils express many defensins while mouse neutrophils only a few (323-325). Similarly, myeloperoxidase levels in mice neutrophils are 80-90% lower than in human neutrophils (326). Significant differences also exist between humans and mice eosinophils granulocytes, monocytes/macrophages, NK cells and mast cells (313).
FcR represents a link between innate and adaptive immune responses. FcαR1 (CD89) is an important IgA receptor in humans and is expressed in neutrophils, eosinophils, monocytes/macrophages, dendritic and Kupffer cells while mice lack FcαR1 and use alternative receptors (310).

There are also clear differences in the adaptive immune responses between humans and mice (310). For example, IL-7R deficiency in mice blocks development of both B and T cells (327). In humans however, only blocks T cells suggesting that B-cell development is not dependent on IL-7 (328). Also, mice, but not humans, exclusively express CD5 and CD23 in B cells, while CD38 is expressed in humans but not in mice plasma cells (329). Mice produce IgA, IgD, IgE, IgG (IgG1, IgG2a, IgG2b and IgG3) and IgM while humans express IgA (IgA1 and IgA2), IgD, IgE and IgG (IgG1, IgG2, IgG3 and IgG4). Interestingly, C57BL/6, C57BL/10, SJL and NOD mice produce IgG2c instead of IgG2a (330). In mice IL-4 induces IgG1 and IgE, while in humans it elicits IgG4 and IgE.

An important component of adaptive immunity is the differentiation of T-cells toward Th1 or Th2 phenotypes. Mosmann et al. (331) first demonstrated in mice the polarization of T-cells. While Th1 and Th2 cells can be found in human diseases the polarization is not so clear. For example, in mice IL-10 is a Th2 cytokine while in humans both Th1 and Th2 cells can make IL-10 (332). Also, in humans IFN-α is produced by several types of cells in response to viral infections inducing Th1 development by activation of STAT4. In contrast, in mice IFN-α does not induce Th1 cells and does not activate STAT4 (333).

From this brief analysis we can conclude that there are many differences between the immune systems of humans and mice and even between various strains of inbreed mice. From the vaccinology perspective it is likely that the antigens that are effective in mice will also be effective in humans. In particular MOMP, already indirectly identified in the original trachoma vaccine trials as a dominant protective antigen, will likely be protective in humans. Other
chlamydial antigens, such as Pmps and CAF, known to elicit humoral and cell mediated immune responses in humans and protection in mice will also likely be protective in humans. However, adjuvant(s) found to be the most efficacious in mice might not be the most effective in humans. To broaden the chances of success, testing adjuvants in inbreed and outbreed mice is recommended. Routes and delivery system for vaccines are fairly restricted in humans. Utilizing one of the most common routes currently used for delivery of human vaccines, intramuscular or subcutaneous, will greatly facilitate implementation. Combining mucosal and systemic routes will likely improve \textit{Chlamydia} vaccine efficacy but it may pose significant safety and practical challenges.

In summary, as Gibbons and Spencer concluded after reviewing the human and the mouse intestinal immunity: “Although the value of animal models should not be underestimated, close attention should be given to the detail; the functional outcome may seem the same but the mechanism might be different (311).” Recent genomic studies support this conclusion (308, 309).

\textbf{Prospects for a human \textit{C. trachomatis} vaccine}

Although great progress has been made over the last four decades, the prospects of implementing a \textit{Chlamydia} vaccine against genital infections in the near future is still under discussion. \textit{C. trachomatis} causes significant morbidity but no mortality. Therefore, the first priority for the implementation of a \textit{C. trachomatis} vaccine is safety. Based on the findings observed during the vaccine trachoma trials, the development of a delayed-type hypersensitivity reaction and increase in susceptibility to infection, or any other negative effect, has to be avoided. The use of a live attenuated or inactivated whole organism vaccine may be justifiable to protect against trachoma, but it is highly unlikely it will be used against genital infections. In addition to safety issues, the costs of producing such a vaccine will be difficult to justify. Therefore, a subunit recombinant vaccine will probably be deployed.
A therapeutic *C. trachomatis* vaccine may have some efficacy if it is delivered before irreversible damage occurs in the female genital tract. Yet, a therapeutic vaccine, although possible, is highly unlikely to be implemented since, at least with our current methodologies, detection of early onset of upper genital tract pathology is a major challenge (334). In the case of trachoma it may be worthwhile to explore the effects of a therapeutic vaccine particularly since there is already evidence in humans that it can be effective (335-337).

Likely most of our current vaccines do not induce sterilizing immunity (239, 240) (240). To block chlamydial infection, a vaccine will have to elicit high levels of mucosal/systemic protective antibodies that are maintained throughout the life of the individual, or at least their reproductive life, a goal not easily achievable. Existing vaccines control the pathogen at the site of entry and therefore, minimize disease, including long-term sequelae. Additionally, they also decrease shedding and therefore transmission. At the population level, this is a critical effect since the number of newly infected individuals can rapidly decline. Using a computer model it was determined that in the case of a *C. trachomatis* vaccine, over a period of at least 10 years, even when its efficacy was only 50%, the decline in new infections will be dramatic (338). This conclusion was supported by other studies that also determined that vaccination was cost effective (339, 340). Vaccinating both males and females will further expedite the control of this pathogen (341).

Based on the experimental work done with single antigen vaccines, nMOMP induces the most robust protection against shedding and infertility. Producing enough nMOMP, by direct extraction from *Chlamydia*, will be extremely expensive. In addition, due to the serovar/serogroup specificity of the protection a vaccine may require to be formulated with MOMP from two to four serovars (45, 137, 342). As shown by Olsen et al. (181), a synthetic MOMP vaccine, that includes specific epitopes from various serovars, is a potentially attractive alternative. Another possibility, is to formulate a multivalent vaccine with rMOMP, and other well-conserved recombinant antigens, such as CPAF and/or the Pmps. Advantages of CPAF
include cross-serovar protection and lack of dependency on its native conformation for protection therefore, greatly facilitating production and formulation. Shortcomings include limited protection against vaginal shedding and infertility. The Pmps are large proteins (>100 kDa) and the recombinant constructs so far tested have only used N-terminal fragments, usually less than 50% of the entire protein. The N-terminal fragments of Pmps are thought to represent the surface exposed domains. Full size Pmps, particularly if they can be refolded into their native conformation, will likely induce robust cross-serovar protective immune responses since they are well conserved among all the human serovars. Phase variation expression could however, limit the protective ability of Pmps especially for PmpG (187, 189). Pmps-based vaccines will therefore require the addition of other antigens. Also, there is yet no evidence that Pmps can protect mice against infertility.

In addition to the antigens, evaluation of adjuvants, routes, and delivery systems for immunization, that are not only effective but also safe and convenient, is going to be critical before a C. trachomatis vaccine is implemented. Based on the findings we have in the mouse model, the adjuvants will have to elicit robust cell mediated and humoral immune responses. The number of adjuvants currently licensed for human use is quite limited. The recent positive experience with the implementation of a highly efficacious systemic subunit vaccine to protect against HPV induced cervical cancer is highly encouraging. HPV infects the transitional zone of the human cervix the same area of the epithelium C. trachomatis infects. This observation implies that it may also be possible to formulate an efficacious Chlamydia vaccine that is delivered by a systemic (intramuscular or subcutaneous) and not a mucosal route, using the appropriate adjuvants. However, in the case of HPV, humoral immune responses appear to play the major role in protection while, for C. trachomatis, cell mediated and humoral immune responses will likely be required to elicit optimal protection (59, 246, 343, 344). Therefore, the adjuvants and routes of immunization for C. trachomatis may differ significantly from those needed for HPV.
Once a vaccine has been found that elicits robust protection in animal models, a set of criteria will need to be defined to measure protection during the human clinical trials. Having a single parameter to assess protection may not be possible. To determine whether or not protection against tubal factor infertility is achieved by vaccination is not a realistic criteria since it will require many years and a very large number of subjects to ascertain that effect. Assessment of PID episodes in the vaccinated and control populations will likely be the most robust end point to evaluate the efficacy of the vaccine. As shown by Westrom et al. (30) single, not multiple, severe PID episodes are the leading cause of infertility in women.

There are other parameters that can assist in evaluating the efficacy of the vaccine. In the mouse model there is a good correlation between vaginal shedding and development of upper genital pathology. The number of animals with positive cultures and the length and severity of vaginal shedding are parameters that could be used to evaluate the efficacy of the vaccine. With these parameters, even if we do not have specific data to determine protection against upper genital pathology in a particular individual, we could estimate the impact on transmission rates and therefore, control of the infection in the population (338, 340).

During the vaccination trials non-invasive radiological techniques, such as Magnetic Resonance Imaging (MRI), could also help to assess the development of upper genital pathology (345-347). However, in addition to the high cost, the lack of sensitivity and specificity may limit the usefulness of our current methods. Serological testing of individuals before and after vaccination, using whole genome Chlamydia protein microarrays to test serum and vaginal samples, could provide supportive information (148, 151, 154, 156). Measurement of inflammatory cytokines and chemokines in cervical vaginal secretions may also assist assess vaccine efficacy (348-350). Importantly, careful, short and long-term follow ups will be required to make sure no negative effects occur at the time of vaccination and later on when the individual is exposed to Chlamydia.
Concluding remarks

Work over the last four decades has identified vaccine components including antigens, adjuvants and immunization routes that can induce significant protection in the mouse model against a _C. muridarum_ genital challenge. In our opinion, to expedite the implementation of _C. trachomatis_ vaccines, the next step should be to test in parallel the most promising formulations reported by various investigators. The two or three more efficacious vaccine formulations could then be evaluated in various inbreed and outbreed mice and other animal models such as the guinea pig and, if necessary, in non-human primates. A cooperative international effort between vaccinologists, government agencies and private companies could result in the implementation of a _C. trachomatis_ vaccine in the next decade. Currently, a MOMP-based vaccine is in phase I clinical trials (26).
References


36


37

Chlamydia trachomatis protects mice against heterotypic challenge infection. Infect Immun 67:3019-3025. 2027


109. Cotter TW, Meng Q, Shen ZL, Zhang YX, Su H, Caldwell HD. 1995. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG


124. **Lu C, Zeng H, Li Z, Lei L, Yeh IT, Wu Y, Zhong G.** 2012. Protective immunity against mouse upper genital tract pathology correlates with high IFN-gamma but low IL-17 T cell...
and anti-secretion protein antibody responses induced by replicating chlamydial

Alderson M, Lobet Y, Cohen J, Mettens P, Reed SG. 2009. Identification and
characterization of novel recombinant vaccine antigens for immunization against genital

against chlamydial genital tract infection after immunization with dendritic cells pulsed ex

127. Lu H, Zhong G. 1999. Interleukin-12 production is required for chlamydial antigen-
pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection.

Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect

live organism recovery and lack of hydrosalpinx in mice infected with plasmid-free

the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial
protection in a murine model of female genitourinary tract infection. Vaccine 28:1454-
1462.

2011. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman

132. Qu Y, Frazer LC, O’Connell CM, Tarantal AF, Andrews CW, Jr., O’Connor SL,
Genital Tract Infection, Pathology, and Immunity in Rhesus Macaques Inoculated with
Wild-Type or Plasmid-Deficient Chlamydia trachomatis Serovar D. Infect Immun 83:
4056-4067.

133. Sigar IM, Schripsema JH, Wang Y, Clarke IN, Cutcliffe LT, Seth-Smith HM,
deficiency in urogenital isolates of Chlamydia trachomatis reduces infectivity and

134. Peterson EM, Markoff BA, Schachter J, de la Maza LM. 1990. The 7.5-kb plasmid
present in Chlamydia trachomatis is not essential for the growth of this microorganism.


136. Wang SP, Grayston JT. 1963. Classification of Trachoma Virus Strains by Protection of

York.

Olinger L, Tatussov RL, Zhao Q, Koonin EV, Davis RW. 1998. Genome sequence of
an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282:754-
759.


173. Pal S, Tatarenkova OV, de la Maza LM. 2015. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Immunology 146:432-443.


186. **Becker E, Hegemann JH.** 2014. All subtypes of the Pmp adhesin family are implicated in chlamydial virulence and show species-specific function. Microbiolopen 3:544-556.


protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect 16:244-252.


prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24:2049-2056.


289. McConnell EL, Basit AW, Murdan S. 2008. Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration. Vaccine 26:639-646.


Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD, Davison BL. 1994. Early...


